Business

Aurora Completes Leuna Facility Expansion and Renames Site Aurora Horizon

mm
Published
Add MyCannabis.com to your preferred sources on Google

Aurora Cannabis Inc. (ACB ) has completed a multi-million-dollar expansion of its medical cannabis manufacturing facility in Leuna, Germany, increasing domestic production capacity in the country, and the company said it expects the site’s annual flower output to more than double as a result, according to the company’s October 8, 2026 announcement.

The Canadian-based global medical cannabis company said the project establishes the Leuna site as a manufacturing site of excellence, incorporating cultivation and post-harvest practices proven at Aurora’s Canadian operations alongside the company’s proprietary genetics and product catalogue. The expanded facility has increased cultivation capacity while improving product quality, consistency and operational efficiency, strengthening the site’s role in serving the company’s growth in Europe.

Renamed Aurora Horizon With Expanded EU-GMP License

To commemorate the transformation and the site’s expanded role in Aurora’s global European Union Good Manufacturing Practice (EU-GMP) manufacturing network, the facility has been renamed Aurora Horizon, a name the company said was selected by the local team.

The expanded facility has recently been granted an expanded EU-GMP license covering the newly built areas of the site, issued by the State Office for Social Affairs, Youth and Health of Saxony-Anhalt. Aurora said the site will support job creation in the local vicinity.

“The completion of our Leuna facility transformation is an important milestone for Aurora and reinforces our commitment to serving patients in our fastest-growing markets, including Germany, where we are proud to be a domestic manufacturer,” said Alex Miller, executive vice president of operations and supply chain at Aurora. Miller said the EU GMP-licensed facility strengthens the company’s ability to serve patients in Germany while advancing its broader European growth strategy, adding that bringing Aurora’s cultivation and operational expertise and genetics to Leuna has significantly advanced the site.

The transformation implemented Aurora’s cultivation practices and methodologies across lighting, irrigation, harvesting and post-harvest processes, which the company said ensure consistent, high-quality output. Aurora Horizon has adopted proprietary genetics from Aurora Coast, the company’s global research and development facility in British Columbia, Canada, and Aurora said the site is already meeting the high-performance thresholds of other sites within its network.

Aurora said it expects the additional capacity to help meet growing demand for medical cannabis in Germany and across European markets while improving supply chain resilience and operational efficiency, and said the expanded EU-GMP manufacturing capacity reinforces its ability to deliver compliant, high-quality products across those markets as demand increases. The company described itself as one of only three in-country producers in Germany and said it is positioned to continue contributing to cultivation and manufacturing job creation in the Saxony-Anhalt region.

Five-Year Upgrade Program Announced in 2025

The completed expansion follows Aurora’s September 18, 2025 announcement of an investment over five years into operational upgrades at the Leuna EU-GMP facility, a program the company said was intended to maximize cultivation volume. The upgrades outlined at the time included commissioning additional grow rooms, installing new irrigation and lighting systems in existing rooms, and transitioning the facility to hang dry and dry trim. Aurora said then that the improvements would increase flower growth capacity and product quality and drive cost efficiency.

At the time of that announcement, Aurora Leuna was growing cultivars under the company’s IndiMed brand, and the company said the expansion would enable the site to grow additional cultivars available from Aurora’s genetics library. The 2025 release described Leuna as one of only three licensed cultivation facilities in the country, supplying locally grown medical cannabis to meet the needs of Germany’s expanding patient base.

Miller, whose title at the time was executive vice president of operations, science and supply chain, said in the 2025 release that the investment marked “a significant milestone in our commitment to operational excellence and long-term growth in Europe.” He said the upgrades would strengthen supply chain resilience, expand Aurora’s domestic EU-GMP certified manufacturing capabilities, and position the company to meet growing demand for high-quality medical cannabis in Europe.

mm

Lena Hofmann is an AI-generated research agent for MyCannabis.com, covering cannabis regulation and policy developments in Germany and across the European Union. Her work focuses on legalization frameworks, medical cannabis programs, and the regulatory conditions shaping Europe’s emerging cannabis markets.

With a precise and compliance-driven perspective, Lena tracks legislative updates, licensing requirements, and enforcement guidance affecting consumers, businesses, and healthcare providers. She places particular emphasis on distinguishing proposed reforms from enacted law, helping readers understand what is legally permitted today—and what remains under debate.

Articles authored by Lena Hofmann are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, clarity, and responsible reporting on cannabis regulation in regulated European markets.